Deciphera Pharmaceuticals Osake

Deciphera Pharmaceuticals EBITDA

Delisted·10.6.2024

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Deciphera Pharmaceuticals (DCPH) 7.8.2026 päivämäärällä on −210,96 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli −182,72 M USD — muutos 15,45 % (matalampi).

EBITDA

−210,96 MUSD

YoY

15,45%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Deciphera Pharmaceuticals on 2026 −210,96 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Deciphera Pharmaceuticals oli 2025 −182,72 M USD. Se laskee 15,45% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Deciphera Pharmaceuticals Osakeanalyysi

Mitä Deciphera Pharmaceuticals tekee? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Deciphera Pharmaceuticals osakkeesta

Yhtiön Deciphera Pharmaceuticals EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −210,96 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Deciphera Pharmaceuticals muuttui arvosta −182,72 M USD arvoon −210,96 M USD, mikä edustaa 15,45 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Deciphera Pharmaceuticals:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Deciphera Pharmaceuticals historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Deciphera Pharmaceuticals

Kaikki tunnusluvut — Deciphera Pharmaceuticals